Tech Company Financing Transactions
BioPorto A/S Funding Round
Private investors invested in a $4.8 million venture round for BioPorto A/S. This VC investment round was announced on 4/25/2025.
Transaction Overview
Company Name
Announced On
4/25/2025
Transaction Type
Venture Equity
Amount
$4,760,000
Round
Undisclosed
Investors
private investors (Hanne Foss)
Proceeds Purpose
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers -- tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Tuborg Havnevej 15, st
Hellerup, 2900
DK
Hellerup, 2900
DK
Phone
Website
Email Address
Overview
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers -- tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company's flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with curr
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Eriksen
Chief Financial Officer
Niels Nielsen
Browse more venture capital transactions:
Prev: 4/25/2025: Noxtua venture capital transaction
Next: 4/25/2025: Reducto venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs